Patents by Inventor Sandesh Seth
Sandesh Seth has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240158528Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.Type: ApplicationFiled: January 10, 2024Publication date: May 16, 2024Applicant: ACTINIUM PHARMACEUTICALS, INC.Inventors: Mark BERGER, Keisha THOMAS, Sandesh SETH, Dale Lincoln LUDWIG
-
Patent number: 11912780Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.Type: GrantFiled: October 25, 2018Date of Patent: February 27, 2024Assignee: ACTINIUM PHARMACEUTICALS, INC.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20230302167Abstract: The invention provides compositions and methods for treating cancers and proliferative disorders, including solid tumor cancers and non-myeloid hematological malignancies, using radioconjugates targeting CD33, alone or in combination with one or more radioconjugates targeting other cancer-associated targets such as DR5, 5T4, HER2, HER3, and TROP2, antibody drug conjugates targeting these or other cancer-associated targets, therapeutic antibodies targeting these or other cancer-associated targets, chemotherapy agents and regimens, and immune checkpoint inhibitors.Type: ApplicationFiled: August 8, 2022Publication date: September 28, 2023Inventors: Mary M. Chen, Avinash Desai, Dale L. Ludwig, Mark Berger, Sandesh Seth
-
Publication number: 20230248855Abstract: Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities such as VEGF or VEGFR inhibitors. The effective amount of the radiolabeled HER3-targeting agent may be a maximum tolerated dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose.Type: ApplicationFiled: December 23, 2022Publication date: August 10, 2023Inventors: DALE L LUDWIG, Eileen Geoghegan, Sandesh Seth, Paul Diamond
-
Publication number: 20230132400Abstract: Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 are disclosed. One or both of the anti-CD33 and anti-CD38 antibodies may be labeled with a radioisotope. The antibodies may be administered sequentially or simultaneously. Moreover, each antibody may be administered according to a specific dosing schedule, wherein the administration may be sequential (i.e., one antibody dosing schedule is completed before the next antibody dosing schedule is started) or simultaneous.Type: ApplicationFiled: November 13, 2018Publication date: April 27, 2023Applicant: Actinium Pharmaceuticals, Inc.Inventors: Sandesh SETH, Keisha THOMAS
-
Publication number: 20220378955Abstract: Compositions and methods useful for the treatment of hemoglobinopathies and hematological diseases are disclosed herein. The compositions include an actinium-225 labeled anti-CD45 antibody (BC8) formulated as a single patient dose that is wholly deliverable to a patient in a single dose. The actinium-225 labeled anti-CD45 may be administered alone or in combination with additional therapeutic agents, such as other immunotherapeutics or a radiosensitizing agent, or additional therapeutic interventions, such as bone marrow transplant or adoptive cell therapies.Type: ApplicationFiled: September 17, 2020Publication date: December 1, 2022Inventors: Dale LUDWIG, Sandesh SETH
-
Publication number: 20220288244Abstract: Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRP?-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRP?.Type: ApplicationFiled: April 21, 2022Publication date: September 15, 2022Inventors: Dale L Ludwig, Sandesh Seth, Paul Diamond
-
Publication number: 20220251239Abstract: Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRP?-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRP?.Type: ApplicationFiled: April 20, 2022Publication date: August 11, 2022Inventors: Dale L Ludwig, Sandesh Seth, Paul Diamond
-
Publication number: 20220211886Abstract: Provided are compositions and methods for treating cancers and precancerous proliferative disorders in a mammalian subject that involve the combination use of a radiotherapeutic agent, such as a radiolabeled CD33, DR5, 5T4, HER2, HER3, or TROP2 targeting agent, and a CD47 checkpoint inhibitor, such as a SIRP?-IgG Fc fusion protein or a monoclonal antibody against CD47 or SIRP?.Type: ApplicationFiled: March 23, 2022Publication date: July 7, 2022Inventors: Dale L Ludwig, Sandesh Seth, Paul Diamond
-
Publication number: 20220143228Abstract: Provided are compositions and methods for treating a solid cancer such as a HER3-positive tumor in a subject by administering an effective amount of a HER3-targeting agent labeled with a radionuclide such as 225Ac, 177Lu, 131I, 90Y, 213Bi, 211At, 213Bi, 227Th, or 212Pb, alone or in combination with other therapeutic agents or modalities. The effective amount of the radiolabeled HER3-targeting agent may be a maximum tolerate dose administered in a single bolus or in fractionated doses that together equal the maximum tolerated dose.Type: ApplicationFiled: November 22, 2021Publication date: May 12, 2022Inventors: Dale L Ludwig, Eileen Geoghegan, Sandesh Seth, Paul Diamond
-
Publication number: 20220125962Abstract: This invention provides a compositions of matter comprising a therapeutic protein population (such as a HuM195 antibody population) wherein (a) each therapeutic protein in the population is conjugated to one or more actinium atoms, (b) each actinium atom is either 227Ac or 225Ac, and (c) the molar ratio of 227Ac to 225Ac in the composition is at least 1:1, This invention also provides related synthetic compositions and methods, as well as methods for treating hematologic malignancies.Type: ApplicationFiled: November 27, 2019Publication date: April 28, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventors: Dale Ludwig, Steve O'Loughlin, Vimal Patel, Nitya Ray, Sandesh Seth
-
Publication number: 20220072167Abstract: This invention provides a method for treating a subject afflicted with cancer, comprising administering to the subject (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets cancer cells in the subject, wherein the amounts of the PARP inhibitor and labeled agent, when administered in conjunction with one another, are therapeutically effective. This invention also provides a method for inducing the death of a cancer cell, comprising contacting the cell with (i) a PARP inhibitor in conjunction with (ii) a radioisotope-labeled agent that targets the cancer cell, wherein the amounts of PARP inhibitor and labeled agent, when concurrently contacted with the cell, are effective to induce the cell's death.Type: ApplicationFiled: January 2, 2020Publication date: March 10, 2022Applicant: Actinium Pharmaceuticals, Inc.Inventors: Dale Ludwig, Sandesh Seth
-
Publication number: 20210198359Abstract: This invention provides a method for depleting a subject's immune cells, where the method includes administering to the subject an effective amount of a radiolabeled anti-CD45 antibody. This invention also provides a method for treating a subject afflicted with cancer, where the method includes (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's lymphocytes, and (ii) after a suitable time period, performing adoptive cell therapy on the subject to treat the subject's cancer. Finally, this invention provides an article of manufacture including (a) a radiolabeled anti-CD45 antibody, and (b) a label instructing the user to administer to a subject an amount of the antibody effective to deplete the subject's immune cells.Type: ApplicationFiled: October 25, 2018Publication date: July 1, 2021Applicant: Actinium Pharmaceuticals, Inc.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20200308280Abstract: Methods for the treatment of a proliferative disorder include administration of a radiolabeled anti-CD45 antibody in concert with an adoptive cell therapy. The adoptive cell therapy may include administration of cells expressing a chimeric antigen receptor or a T-cell receptor (CAR/TCR). The radiolabeled anti-CD45 antibody may be administered before administration of the population of cells expressing the CAR/TCR, either alone or in conjunction with standard lymphodepletion agents. The radiolabeled anti-CD45 antibody may be administered after administration of the population of cells expressing the CAR/TCR in preparation for transplantation of autologous stem cells and/or administration of a second effective amount of the populations of cells expressing the CAR/TCR. These methods may improve treatment outcomes for hematological malignancies including solid tumors, and/or may lessen side effects associated with adoptive cell therapies.Type: ApplicationFiled: October 25, 2018Publication date: October 1, 2020Applicant: Actinium Pharmaceuticals, Inc.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20200283539Abstract: Methods for treating a hematological disease or disorder or a solid cancer by administering an effective amount of a combination immunotherapy including an antibody against an epitope of CD33 and an antibody against an epitope of CD38 are disclosed. One or both of the anti-CD33 and anti-CD38 antibodies may be labeled with a radioisotope. The antibodies may be administered sequentially or simultaneously. Moreover, each antibody may be administered according to a specific dosing schedule, wherein the administration may be sequential (i.e., one antibody dosing schedule is completed before the next antibody dosing schedule is started) or simultaneous.Type: ApplicationFiled: November 13, 2018Publication date: September 10, 2020Applicant: Actinium Pharmaceuticals, Inc.Inventors: Sandesh SETH, Keisha THOMAS
-
Publication number: 20200255520Abstract: This invention provides a method for depleting a subject's hematopoietic stem cells comprising administering to the subject an effective amount of a radiolabeled anti-CD45 antibody, such as 131I-BC8 or 225Ac-BC8. This invention also provides a method for treating a subject afflicted with a non-cancerous disorder treatable via genetically edited cell therapy comprising (i) administering to the subject an amount of a radiolabeled anti-CD45 antibody effective to deplete the subject's hematopoietic stem cells, and (ii) after a suitable time period, performing the therapy on the subject to treat the subject's disorder. Finally, this invention provides articles of manufacture for performing the subject methods.Type: ApplicationFiled: October 25, 2018Publication date: August 13, 2020Applicant: Actinium Pharmaceuticals, Inc.Inventors: Mark Berger, Keisha Thomas, Sandesh Seth, Dale Lincoln Ludwig
-
Publication number: 20200121815Abstract: Pharmaceutical compositions comprising a radionuclide labelled monoclonal antibody against CD38, and methods of treating a hematological malignancy, inhibiting growth and/or proliferation of a cell expressing CD38, or treating a disease or disorder involving cells expressing CD38 are disclosed. An exemplary monoclonal antibody includes daratumumab labeled with actinium (225Ac).Type: ApplicationFiled: July 31, 2018Publication date: April 23, 2020Applicant: Actinium Pharmaceuticals, Inc.Inventors: Sandesh Seth, Keisha Thomas